13F Holdings
中文EN

SPRY ARS Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1671858 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-14.5%
TTM net income YoY-149.7%
TTM EPS YoY-148.1%
Revenue 3-yr CAGR1,496.8%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-161.5%
Net margin-163.6%
FCF margin-149.9%
EBITDA margin-160.2%

Returns

ROE-294.6%
ROA-64.0%
ROIC (approx.)-116.0%
Asset turnover0.39x

Leverage & solvency

Liabilities / assets104.8%
Debt / equity—
Current ratio3.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-5.4%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$84.28M$89.15M$30,000$1.32M$5.51M
Cost of revenue——$0——
Gross profit——$30,000——
R&D expense$13.18M$19.58M$20.27M$18.38M$20.27M
SG&A expense$230.12M$71.67M$47.28M$603,000$4.69M
Operating income-$179.45M-$3.08M-$67.52M-$35.52M-$19.45M
Pretax income-$171.38M$8.29M-$54.37M——
Income tax-$80,000$288,000$0$0$0
Net income-$171.30M$8.00M-$54.37M-$34.68M-$20.24M
EBITDA-$178.08M-$3.00M-$67.42M-$35.42M-$19.24M
EPS (basic)-1.740.08-0.57-0.87-0.70
EPS (diluted)-1.740.08-0.57-0.87-0.70
Weighted avg. shares (diluted)98.57M102.39M95.22M39.96M28.87M
Banking
Net interest income————$106,000
Balance sheet
Cash & equivalents$41.32M$50.82M$70.97M$210.52M$60.06M
Short-term investments$203.67M$263.20M$157.39M$63.86M$0
Receivables$25.35M$8.18M$0——
Inventory$31.42M$10.52M$0——
Current assets$284.90M$334.30M$231.73M$277.70M$60.73M
PP&E, net$2.46M$1.07M$574,000$329,000$72,000
Intangibles$14.45M$7.37M$0——
Total assets$327.65M$351.15M$233.19M$281.44M$61.45M
Current liabilities$39.15M$23.44M$2.39M$5.44M$8.19M
Long-term debt$96.37M$0———
Total debt$96.37M$0———
Total liabilities$213.39M$94.36M$2.43M$8.55M$16.68M
Shareholders' equity$114.26M$256.80M$230.76M$272.89M-$31.27M
Net debt$55.06M-$50.82M———
Shares outstanding99.29M97.95M96.41M93.94M30.37M
Cash flow statement
Operating cash flow-$170.87M$13.55M-$59.27M-$40.08M-$17.56M
Capital expenditure$339,000$563,000$175,000$199,000$55,000
Free cash flow-$171.21M$12.98M-$59.44M-$40.28M-$17.62M
Investing cash flow$56.77M-$106.10M-$87.18M-$199,000-$55,000
Financing cash flow$104.60M$72.40M$6.90M$190.73M$53.16M
Depreciation & amortization$1.37M$79,000$100,000$100,000$213,000
Stock-based compensation$22.09M$14.53M$9.23M$5.84M$2.83M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.